60 Degrees Pharma

Call Directions Website Contact the practice

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from 60 Degrees Pharma, Medical and health, 60 Degrees Pharmaceuticals, Inc 1025 Connecticut Avenue NW Suite 1000, Washington D.C., DC.

60 Degrees Pharmaceuticals was founded in 2010 with a mission to help people live longer, healthier lives by discovering, developing, and distributing new best-in-class medicines for the treatment and prevention of infectious diseases.

11/06/2026

Physicians like Dr. Richard Horowitz have spent years seeing the impact of babesiosis firsthand.

His experience speaks to a need we share his urgency around: more treatment options for patients, particularly when infection persists or returns.

That’s why, at 60 Degrees Pharmaceuticals, we’re studying tafenoquine as a potential treatment across severe acute, persistent or relapsing, and chronic babesiosis.

Thank you, Dr. Horowitz, for your years of patient care and advocacy, and for continuing to bring attention to the challenges these patients face.

Learn more about our babesiosis research and clinical trials at the link in our bio.

11/05/2026

How many people are really affected by babesiosis?

It's a harder question to answer than you might think.

But the available estimates suggest reported cases are likely missing a significant number of patients.

Between 2011 and 2019, 16,456 cases were reported in the United States. Yet insurance claims suggest at least 25,000 patients seek care for babesiosis every year.

And even those estimates may miss people whose infections go unrecognized and undiagnosed.

When the burden is underestimated, the need for better recognition and treatment options can be underestimated, too. Our goal is to change that.

Swipe through to see how the estimates compare, and learn more about our babesiosis research and clinical trials at the link in our bio.

11/02/2026

Our market research estimates that roughly 10 million Americans are living with fatigue that has lasted six months or longer.

For many, that can mean making plans around how much energy they have today and how long it may take to recover afterward.

Persistent fatigue appears across conditions including chronic babesiosis, Lyme disease, Long COVID, and chronic fatigue syndrome.

In this clip from The Healing Grove, Dr. Geoff Dow talks about what researchers might learn by studying that shared symptom across diagnoses.

We’re studying severe, persistent fatigue in patients with chronic babesiosis through our B-FREE trial – you can learn more about the trial at the link in our bio.

10/29/2026

Roughly 1 in 10 blacklegged ticks tested in a Hudson Valley study carried two or more disease-causing pathogens.

The most common combination was the pathogens that cause Lyme disease and babesiosis.

Co-infections are not as rare as many believe. And the problem is, that while the infections can cause overlapping symptoms, they often require different treatments.

So, if someone finishes treatment for Lyme and still feels sick, Babesia may be one possibility their clinician needs to consider.

Swipe through for a closer look at the findings, and learn more about our babesiosis research at the link in our bio.

10/27/2026

You’ve heard us talk about babesiosis. Today, we’d like to hear from you.

If you’ve lived with babesiosis or supported someone who has, what do you wish more people understood?

Finish the sentence in the comments: “I wish more people understood that babesiosis can…”

We’ll be reading your responses.

10/26/2026

Babesiosis doesn’t look the same for every patient.

Some people may never develop symptoms. Others experience an acute illness and recover with treatment. For some patients, particularly those at higher risk, the infection can persist or return after treatment.

That variation is part of what makes babesiosis so complex to study. There isn’t one patient experience, one disease course, or one set of challenges that represents everyone.

At 60 Degrees Pharmaceuticals, our research looks across severe acute, persistent relapsing, and chronic babesiosis to better understand those differences and what they could mean for treatment.

Because better answers start with understanding the full picture. Learn more through the link in our bio.

10/22/2026

Patients living with chronic babesiosis have waited a long time to see research reflect their lived experiences.

For many, severe fatigue continues well beyond the initial illness. Yet there is still no FDA-approved treatment specifically for chronic babesiosis.

Our B-FREE Phase 2 trial is studying tafenoquine in patients with severe, persistent fatigue.

We’re working to understand whether treatment may help with the symptoms affecting their daily lives while also addressing Babesia infection.

Amy Proal, PhD, Scientific Director at CoRE, shares what this step means to her, and we’re so grateful to work alongside her and many other incredible scientists, researchers, physicians, and advocates as we pursue better answers for patients.

Learn more about B-FREE at the link in our bio.

10/20/2026

Every patient’s experience with babesiosis is unique.

A patient hospitalized with babesiosis faces a different challenge from someone whose infection keeps returning. Others are living with severe fatigue that continues long after the initial illness.

That’s why we’re studying tafenoquine across three areas: severe acute babesiosis, persistent or relapsing infection, and chronic babesiosis with severe fatigue.

Each clinical trial is designed to answer a different question about where tafenoquine may help and which patients could benefit. Together, they can give clinicians stronger evidence for forms of babesiosis that remain difficult to treat.

See the three areas we’re studying in the graphic, and explore our clinical trials at 60degreespharma.com.

10/19/2026

Patient stories helped bring tafenoquine into the babesiosis research conversation.

In this clip from The Healing Grove, Dr. Geoff Dow explains why listening to patients is an important starting point. Clinical trials can then test whether the benefits they describe hold up across a larger group.

Watch the clip and learn more about our tafenoquine research for babesiosis at the link in our bio.

10/15/2026

What happens when your experience with babesiosis doesn’t match the textbook description?

For many patients, that means years without answers and care.

Most patients improve with standard treatment, but not every case follows the same path. Some infections can return, some are difficult to diagnose, and some patients continue struggling even when they do not fit the usual “high-risk” profile.

A narrow understanding of babesiosis can leave those patients falling through the cracks.

Swipe through three myths we need to clear up, and learn how we’re studying acute, relapsing, and chronic babesiosis at the link in our bio.

Address

60 Degrees Pharmaceuticals, Inc 1025 Connecticut Avenue NW Suite 1000
Washington D.C., DC
20036

Telephone

(202)3275422

Website

https://60degreespharma.com/

Alerts

Be the first to know and let us send you an email when 60 Degrees Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.